← Back to Search

Behavioural Intervention

Virtual Reality for Chronic Pain (VR TMD EEG Trial)

N/A

Recruiting

Research Sponsored by University of Maryland, Baltimore

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age (18-88 years)

English speaker (written and spoken)

Must not have

Present or past degenerative neuromuscular disease

Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up we will acquire 2-10 min of baseline eeg with open eyes and 2-10 min of eeg with closed eyes. this measurement will occur at each of the four in-person visit approximately every 3 weeks.

Awards & highlights

No Placebo-Only Group

Summary

This trial will compare the effects of immersive virtual reality to a placebo treatment for chronic pain. The goal is to find new non-medication options for managing pain with low risk.

Who is the study for?

This trial is for individuals experiencing chronic pain, specifically in the jaw joint (TMJ Dysfunction). Participants should be interested in trying non-drug treatments. Details on specific inclusion and exclusion criteria are not provided.

What is being tested?

The study is testing an immersive virtual reality system called RelieVRx against a fake VR treatment (Sham-VR) and no VR at all to understand how they affect chronic pain relief.

What are the potential side effects?

Since this trial involves virtual reality, potential side effects may include dizziness, nausea, eye strain or headaches. However, these are generally low-risk compared to medication side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 88 years old.

Select...

I can speak and write in English.

Select...

I experience some level of chronic pain.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have or had a muscle-weakening disease.

Select...

I don't have heart, lung, kidney, liver diseases or any cancer in the last 3 years.

Select...

I have neck pain due to nerve issues or narrowing of the spine.

Select...

I have not been hospitalized for a severe psychiatric condition in the last 3 years.

Select...

I am currently taking antipsychotic medication.

Select...

I have hearing problems that are not corrected.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ we will acquire 2-10 min of baseline eeg with open eyes and 2-10 min of eeg with closed eyes. this measurement will occur at each of the four in-person visit approximately every 3 weeks.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~we will acquire 2-10 min of baseline eeg with open eyes and 2-10 min of eeg with closed eyes. this measurement will occur at each of the four in-person visit approximately every 3 weeks.

This trial's timeline: 3 weeks for screening, Varies for treatment, and we will acquire 2-10 min of baseline eeg with open eyes and 2-10 min of eeg with closed eyes. this measurement will occur at each of the four in-person visit approximately every 3 weeks. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Objective incremental Celsius changes in heat-pain tolerance

Peak alpha frequency (PAF)

Secondary study objectives

Subjective VAS (Visual Analog Scale) scores for mood, situational anxiety, and pain intensity/unpleasantness

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Low impact TMDExperimental Treatment3 Interventions

Other: TMD Phenotype TMD participants will be clinically phenotyped into two between-subject groups based on their score on the Graded Chronic Pain Scale (GCPS). This group will have a GCPS grade 0, 1, and 2a

Group II: High impact TMDExperimental Treatment3 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

RelieVRx

2023

N/A

~20

0 / 9Eligibility criteria met